Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

NCT04079738 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Funder requested termination due to halting internal development of TAK-659

Conditions

AML
AML, Adult

Interventions

DRUG: TAK-659
DRUG: Ixazomib

Sponsor

H Scott Boswell

Collaborators

[object Object]